Targets › GFRAL
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. (UniProt, Q6UXV0)
Open in Phaseline: the race on GFRAL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai JMT-Bio | JMT203 Injection anti-GFRAL monoclonal antibody | GFRAL | Phase 1 | Non Small Cell Lung Cancer | Aug 2027 |
Non Small Cell Lung Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.